Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model

被引:82
作者
Coleman, Ken [1 ]
Levasseur, Premavathy [1 ]
Girard, Anne-Marie [1 ]
Borgonovi, Monica [1 ]
Miossec, Christine [1 ]
Merdjan, Henri [1 ]
Drusano, George [2 ]
Shlaes, David [3 ]
Nichols, Wright W. [4 ]
机构
[1] Novexel SA, Romainville, France
[2] Univ Florida, Coll Med, Inst Therapeut Innovat, Orlando, FL USA
[3] Antiinfect Consulting LLC, Stonington, CT USA
[4] AstraZeneca Pharmaceut LP, Waltham, MA 02451 USA
关键词
IN-VITRO ACTIVITY; PSEUDOMONAS-AERUGINOSA; KLEBSIELLA-PNEUMONIAE; KPC CARBAPENEMASES; INHIBITOR; NXL104; COMBINATION; DRUG; PHARMACOKINETICS; INFECTIONS;
D O I
10.1128/AAC.00080-14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Avibactam is a novel non-beta-lactam beta-lactamase inhibitor that is currently undergoing phase 3 clinical trials in combination with ceftazidime. Ceftazidime is hydrolyzed by a broad range of beta-lactamases, but avibactam is able to inhibit the majority of these enzymes. The studies described here attempt to provide insight into the amount of avibactam required to suppress bacterial growth in an environment where the concentrations of both agents are varying as they would when administered to humans. Following the simulation of a single intravenous dose of the drug, ceftazidime alone had no effect on any test organism, but a ceftazidime-avibactam combination resulted in rapid killing of all of the strains, with growth suppressed for the 8 h of the study. For seven of eight strains, this was achieved with a 1-g-250-mg profile, but a 2-g-500-mg profile was necessary to completely suppress a high-level-AmpC-producing isolate. When ceftazidime was infused continuously for 24 h with a single bolus dose of avibactam, rapid killing of all of the strains was again observed, with growth suppressed for 10 to >24 h. Regrowth appeared to commence once the avibactam concentration dropped below a critical concentration of approximately 0.3 mu g/ml. In a third series of studies, ceftazidime was administered every 8 h for 24 h with avibactam administered at fixed concentrations for short periods during each ceftazidime dose profile. Simulating a 1-g dose of ceftazidime, an avibactam pulse of >0.25 and <0.5 mu g/ml was required to suppress growth for 24 h.
引用
收藏
页码:3366 / 3372
页数:7
相关论文
共 33 条
[1]   Animal model pharmacokinetics and pharmacodynamics: a critical review [J].
Andes, D ;
Craig, WA .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :261-268
[2]  
[Anonymous], 2012, METHODS DILUTION ANT
[3]  
[Anonymous], 53 INT C ANT AG CHEM
[4]  
Berkhout J, 2013, 52 INT C ANT AG CHEM
[5]   Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors [J].
Bhagunde, Pratik ;
Chang, Kai-Tai ;
Hirsch, Elizabeth B. ;
Ledesma, Kimberly R. ;
Nikolaou, Michael ;
Tam, Vincent H. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) :2237-2240
[6]   In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor [J].
Bonnefoy, A ;
Dupuis-Hamelin, C ;
Steier, V ;
Delachaume, C ;
Seys, C ;
Stachyra, T ;
Fairley, M ;
Guitton, M ;
Lampilas, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) :410-417
[7]  
Borgonovi M, 2008, 48 INT C ANT AG CHEM
[8]   Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors [J].
Coleman, Ken .
CURRENT OPINION IN MICROBIOLOGY, 2011, 14 (05) :550-555
[9]   Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid [J].
Craig, WA .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :479-+
[10]   Is all free time above the minimum inhibitory concentration the same:: implications for β-lactam in vivo modelling [J].
DeRyke, C. Andrew ;
Nicolau, David P. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (03) :341-343